Live Analyst Rating Changes 24315 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Steven Lichtman
WB

Steven Lichtman

William Blair
Wall Street Analyst
★★★☆☆
#1915
on 13Foresight · ranked by our own returns
60%
Success Rate
+7.2%
Average Return
24 of 40 calls profitable · -2.3% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 60% of Steven Lichtman's ratings turned a profit when each position was held for 1 year — averaging +7.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

31 Buy 11 Hold 0 Sell
Steven's Stock Coverage 34 ratings · 2026-08-13
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
OWLT
Owlet
 Aug 12, 2026 BUY Strong Buy
+101.8% avg upside
11 analysts
 — +7.9% ·
CH:ALC
Alcon
 Aug 12, 2026 HOLD Strong Buy
+20.1% avg upside
35 analysts
 — · ·
RXST
RxSight
 Aug 07, 2026 HOLD Hold
+26.8% avg upside
13 analysts
 — +12.0% ·
SGHT
Sight Sciences
 Aug 06, 2026 BUY Buy
+10.7% avg upside
13 analysts
 — +17.2% ·
ZBH
Zimmer Biomet Holdings
 Aug 06, 2026 HOLD Buy
+17.5% avg upside
38 analysts
 — +2.5% ·
PODD
Insulet
 Aug 05, 2026 BUY Strong Buy
+50.4% avg upside
32 analysts
 — +8.2% ·
DXCM
Dexcom
 Jul 31, 2026 BUY Strong Buy
+16.5% avg upside
32 analysts
 — +9.6% ·
BFLY
Butterfly Network
 Jul 31, 2026 BUY Strong Buy
-42.1% avg upside
8 analysts
 — +30.4% ·
SYK
Stryker
 Jul 31, 2026 BUY Strong Buy
+6.5% avg upside
37 analysts
 — +6.2% ·
GKOS
Glaukos
 Jul 30, 2026 BUY Strong Buy
-10.0% avg upside
21 analysts
 — +12.4% ·
MMED
MiniMed Group, Inc.
 Jun 17, 2026 BUY Strong Buy
+8.6% avg upside
14 analysts
 — +38.3% ·
COO
Cooper Co
 Jun 05, 2026 BUY Buy
+73.8% avg upside
21 analysts
 — +13.9% ·
ENOV
Enovis
 May 08, 2026 BUY Strong Buy
+172.1% avg upside
39 analysts
 — -3.2% ·
MNKD
MannKind
 Sep 05, 2025 BUY Buy
+82.4% avg upside
22 analysts
$15.00
288.18% Upside
 -30.5% ·
BSX
Boston Scientific
 Aug 03, 2025 HOLD Strong Buy
+31.9% avg upside
38 analysts
$118.00
128.13% Upside
 -54.6% ·
BWAY
Brainsway
 May 14, 2025 BUY Strong Buy
-15.9% avg upside
10 analysts
$7.50
55.85% Downside
 +217.8% ·
GMED
Globus Medical
 May 09, 2025 HOLD Strong Buy
+8.4% avg upside
24 analysts
$78.00
8.68% Downside
 +39.6% ·
MMSI
Merit Medical Systems
 Feb 26, 2025 BUY Strong Buy
+8.4% avg upside
15 analysts
$116.00
26.76% Upside
 -22.3% ·
ANGO
AngioDynamics
 Jan 10, 2025 BUY Strong Buy
+12.9% avg upside
9 analysts
$16.00
1.36% Upside
 -19.8% ·
PEN
Penumbra
 Dec 16, 2024 BUY Buy
+1.2% avg upside
23 analysts
$275.00
16.01% Downside
 +24.6% ·
STAA
Staar Surgical
 Nov 01, 2024 HOLD Hold
+33.5% avg upside
16 analysts
 — -9.4% ·
MDT
Medtronic
 Aug 21, 2024 HOLD Buy
+6.5% avg upside
38 analysts
$94.00
3.59% Upside
 +7.5% ·
TNDM
Tandem Diabetes Care
 Aug 02, 2024 BUY Buy
+40.3% avg upside
29 analysts
$58.00
148.74% Upside
 -63.0% ·
IART
Integra Lifesciences
 May 07, 2024 HOLD Buy
+149.7% avg upside
21 analysts
 — -49.2% ·
MODD
Modular Medical
 Sep 19, 2023 BUY Strong Buy
+270.9% avg upside
3 analysts
$3.50
73.36% Upside
 +94.8% ·
MOTS
Motus Gi Holdings
 Feb 06, 2023 HOLD Buy
+49433233.3% avg upside
6 analysts
 — · ·
ORGO
Organogenesis Holdings
 Aug 10, 2022 HOLD Strong Buy
+540.1% avg upside
8 analysts
 — -42.8% ·
HSDT
Solana Company
 Dec 31, 2020 HOLD Strong Buy
+1182.6% avg upside
8 analysts
 — · ·
LFWD
Lifeward
 Dec 18, 2018 HOLD Strong Buy
-5.5% avg upside
8 analysts
 — · ·
CI
Cigna
 Feb 08, 2018 BUY Strong Buy
+25.4% avg upside
29 analysts
$237.00
14.77% Downside
 -4.2% ·
CYPH
Cypherpunk Technologies
 May 27, 2016 HOLD Buy
+1194.4% avg upside
9 analysts
 — · ·
NUWE
Nuwellis
 Mar 04, 2016 HOLD Strong Buy
+1501.9% avg upside
7 analysts
 — · ·
NSPR
InspireMD
 Mar 13, 2015 HOLD Strong Buy
+346.3% avg upside
8 analysts
 — · ·
STXS
Stereotaxis
 Oct 07, 2011 HOLD Strong Buy
+172.2% avg upside
7 analysts
 — -88.8% ·
🔒 29 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Steven Lichtman — Frequently Asked Questions
How accurate are Steven Lichtman's stock ratings?
Based on the calls 13Foresight could measure, about 60% of Steven's ratings were profitable over a one-year hold, with an average return of +7.2% per rating, or -2.3% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Steven ranked on 13Foresight?
Steven Lichtman is currently ranked #1915 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Steven cover?
Steven most recently has ratings on OWLT, CH:ALC, RXST, SGHT, ZBH, PODD, DXCM, BFLY, SYK, GKOS, MMED, COO and 22 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.